Saturday 17 October 2026
Export LAB’s income statement to Excel — free account
Standard BioTools Inc.
LAB Healthcare Medical Devices
In the quarter to June 2026, revenue fell 7.62%, EPS grew 22.2%, free cash flow grew 52.8% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.63
0.03
−4.55%
Follow LAB
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
4 | 4 | 5 | 3 | 1 | 5 | 4 | 6 | 3 | 2 |
P/S ratio |
5.72 | 6.79 | 1.65 | 1.04 | 2.28 | 3.13 | 1.98 | 3.03 | 2.02 | 2.11 |
Altman Z-Score |
(0.82) | 0.00 | (3.95) | (3.20) | (2.99) | (1.38) | (1.96) | (1.49) | (2.04) | (1.69) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(1.44) | (0.87) | (9.63) | (5.45) | (9.28) | (5.78) | (5.97) | (4.80) | (5.51) | (4.62) |
Beneish M-Score |
(2.93) | (2.23) | (2.94) | (3.56) | (2.94) | (2.77) | (2.66) | (2.95) | (3.02) | (3.50) |
P/Operating CF |
(410.49) | (43.97) | (12.50) | (5.31) | (42.43) | (115.80) | (42.11) | (535.74) | 310.84 | (20.52) |
P/B ratio |
1.15 | 1.31 | 0.00 | 0.00 | 3.14 | 3.11 | 1.51 | 4.74 | 6.64 | 4.14 |
Price to Tangible BV |
1.72 | 1.87 | 0.00 | 0.00 | 0.00 | 0.00 | 70.34 | 0.00 | 0.00 | 0.00 |
EV/Sales |
3.59 | 3.63 | 0.66 | 0.01 | 2.60 | 3.05 | 1.96 | 3.70 | 3.31 | 3.41 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(4.12) | (2.30) | (1.61) | (0.01) | (7.71) | (27.30) | (6.52) | (16.60) | (14.01) | (9.09) |
EV/FCF |
(3.43) | (2.09) | (1.32) | (0.01) | (5.31) | (12.12) | (5.17) | (13.01) | (10.46) | (6.99) |
Quick Ratio |
1.86 | 4.67 | 1.23 | 4.21 | 0.94 | 1.73 | 2.36 | 2.98 | 2.34 | 2.51 |
Current Ratio |
4.19 | 5.70 | 1.45 | 4.81 | 1.45 | 2.17 | 2.93 | 3.38 | 2.83 | 3.28 |
Net Debt/EBITDA |
1.84 | 2.48 | 1.69 | 0.99 | (0.83) | 0.35 | 0.09 | (3.30) | (3.35) | (2.47) |
Debt/Assets |
0.05% | 0.05% | 2.78% | 16.63% | 25.82% | 17.61% | 21.02% | 56.66% | 67.94% | 63.63% |
Debt/Equity |
0.00 | 0.00 | 0.06 | 0.28 | 0.75 | 0.41 | 0.36 | 2.39 | 6.31 | 3.66 |
Asset Turnover |
0.14 | 0.19 | 0.30 | 0.29 | 0.44 | 0.47 | 0.41 | 0.38 | 0.34 | 0.31 |
Operating CF/Net income |
0.99 | 0.78 | 0.58 | 0.47 | 0.74 | 0.29 | 0.54 | 0.43 | 0.40 | 0.52 |
Capex/Depreciation |
(1.00) | (0.89) | (0.20) | (0.27) | (0.82) | (0.69) | (0.14) | (0.01) | (0.09) | (0.28) |
Interest Coverage |
(4,240.35) | (38.45) | (16.77) | (26.83) | (17.65) | (14.29) | (12.11) | (3.47) | (10.02) | (12.58) |
| (16.72%) | (114.25%) | 65.05% | (2,895.83%) | (50.71%) | (36.23%) | (57.41%) | (114.53%) | (143.84%) | (90.39%) | |
| (12.69%) | (39.53%) | (20.93%) | (57.13%) | (19.75%) | (17.99%) | (22.79%) | (19.97%) | (20.39%) | (22.47%) | |
ROIC |
(29.07%) | (44.48%) | (83.57%) | (56.35%) | (30.73%) | (24.97%) | (21.51%) | (20.23%) | (22.37%) | (24.23%) |
Return on Tangible Assets |
(20.51%) | (55.56%) | (102.16%) | (99.52%) | (117.23%) | (65.50%) | (90.83%) | (60.00%) | (82.22%) | (90.79%) |
Average Days of Receivables |
57.45 | 59.12 | 67.48 | 64.39 | 51.21 | 67.17 | 59.09 | 53.80 | 53.89 | 51.06 |
Research and Development Expense of Revenue |
30.45% | 31.68% | 24.40% | 38.17% | 29.06% | 26.39% | 26.99% | 26.58% | 30.24% | 36.78% |
Selling, General and Administrative Expense of Revenue |
128.75% | 113.24% | 82.32% | 104.43% | 75.73% | 70.87% | 72.05% | 70.63% | 78.01% | 89.24% |
Intangible Assets out of Total Assets |
0.00 | 0.23 | 0.33 | 0.30 | 0.49 | 0.45 | 0.57 | 0.53 | 0.60 | 0.60 |
Share Based Compensation of Revenue |
34.70% | 34.87% | 12.34% | 15.19% | 12.33% | 10.46% | 9.72% | 9.76% | 8.92% | 13.27% |
Graham Net Nets |
0.64 | 0.38 | (0.01) | 0.47 | (0.37) | (0.16) | (0.06) | (0.31) | (0.79) | (0.71) |
Graham Number |
0.00 | 0.00 | 6.32 | 7.56 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(15.63%) | (31.43%) | (42.79%) | (187.69%) | (19.90%) | (12.17%) | (29.02%) | (17.40%) | (30.50%) | (34.52%) |
Free Cash Flow Yield |
(18.27%) | (25.63%) | (30.00%) | (98.03%) | (21.52%) | (8.04%) | (19.08%) | (9.41%) | (15.70%) | (23.11%) |
Revenue per Share |
0.22 | 0.26 | 1.34 | 1.25 | 1.72 | 1.92 | 1.76 | 2.85 | 3.09 | 3.60 |
Operating CF per Share |
(0.19) | (0.41) | (0.55) | (1.14) | (0.58) | (0.21) | (0.53) | (0.64) | (0.73) | (1.35) |
Capex per Share |
(0.02) | (0.02) | (0.04) | (0.05) | (0.17) | (0.18) | (0.04) | (0.01) | (0.05) | (0.17) |
Free Cash Flow per Share |
(0.22) | (0.43) | (0.58) | (1.19) | (0.76) | (0.39) | (0.57) | (0.64) | (0.78) | (1.52) |
Cash per Share |
0.49 | 0.83 | 1.45 | 2.12 | 0.38 | 0.95 | 0.88 | 2.41 | 1.91 | 2.05 |
Shareholders Equity per Share |
1.11 | 1.34 | 2.06 | 2.93 | 1.25 | 1.93 | 2.30 | 1.82 | 0.94 | 1.84 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.11 | 1.34 | 2.06 | 2.93 | 1.25 | 1.93 | 2.30 | 1.82 | 0.94 | 1.84 |
Free Cash Flow |
(82.65) | (151.81) | (46.12) | (93.19) | (57.32) | (28.13) | (37.74) | (25.57) | (25.71) | (44.20) |
Working Capital |
345.96 | 309.99 | 48.89 | 165.37 | 22.50 | 63.41 | 63.28 | 89.52 | 61.33 | 67.17 |
Capital Expenditures |
(8.30) | (8.35) | (2.83) | (3.82) | (13.26) | (12.72) | (2.53) | (0.37) | (1.62) | (5.06) |
Net Current Asset Value |
310.80 | 235.26 | (1.65) | 48.29 | (108.55) | (68.04) | (15.10) | (104.42) | (161.61) | (156.49) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.10 | 0.09 | 0.03 | 0.04 | 0.10 | 0.09 | 0.02 | 0.00 | 0.02 | 0.05 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.43 | 0.41 | 0.58 | 0.56 | 0.58 | 1.05 | 2.19 | 2.83 | 1.54 | 1.10 |
Cash ROIC |
(13.50%) | (19.85%) | (16.06%) | (20.24%) | (29.53%) | (10.63%) | (14.09%) | (7.53%) | (8.89%) | (14.37%) |
Accounts Receivable Turnover |
6.06 | 5.29 | 5.76 | 5.50 | 5.97 | 6.22 | 6.58 | 7.13 | 6.87 | 5.21 |
Accounts Payable Turnover |
8.18 | 6.46 | 6.52 | 6.58 | 6.18 | 7.63 | 11.54 | 12.46 | 12.22 | 9.15 |
Inventory Turnover |
2.10 | 2.23 | 2.66 | 2.88 | 3.02 | 3.27 | 3.94 | 3.65 | 2.84 | 2.42 |
Average Days of Payables |
46.12 | 39.95 | 60.32 | 47.43 | 63.22 | 61.39 | 35.50 | 28.64 | 30.77 | 31.47 |
Days of Inventory on Hand |
170.45 | 164.15 | 134.09 | 128.70 | 124.19 | 131.10 | 95.68 | 92.49 | 110.24 | 159.57 |
Average Receivables |
14.09 | 17.20 | 18.47 | 17.80 | 21.87 | 22.20 | 17.82 | 15.85 | 14.83 | 20.03 |
Average Payables |
5.23 | 7.14 | 8.58 | 9.26 | 9.91 | 7.19 | 4.59 | 4.12 | 4.09 | 5.03 |
Average Inventory |
20.36 | 20.64 | 21.00 | 21.15 | 20.26 | 16.79 | 13.44 | 14.05 | 17.60 | 19.02 |
Average Assets |
590.05 | 467.71 | 356.69 | 332.76 | 299.99 | 294.78 | 284.23 | 295.50 | 296.87 | 338.22 |
Average Common Equity |
448.01 | 161.84 | (114.76) | 6.56 | 116.82 | 146.33 | 112.86 | 51.53 | 42.08 | 84.07 |
Columns are period end dates